Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 4,168 shares at $50.11 ($210K) on 2021-12-13, disclosed to the SEC on 2021-12-15.
Open-market sale of $210k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.11 | 1,518 | $76K | 36.3% |
| 2 | $50.11 | 1,518 | $76K | 36.3% |
| 3 | $52.22 | 390 | $20K | 9.7% |
| 4 | $53.64 | 7 | $375 | 0.2% |
| 5 | $50.00 | 735 | $37K | 17.5% |
| Total | $50.29 avg | 4,168 |
| $210K |
| 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |